A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

June 13, 2019

Primary Completion Date

April 6, 2020

Study Completion Date

January 15, 2021

Conditions
Psoriatic Arthritis
Interventions
DRUG

PF-06700841

Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

OTHER

Placebo

Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.

Trial Locations (48)

1000

"Medical Center Pirogov", Sofia

1036

Qualiclinic Kft., Budapest

1505

"Diagnostic-Consulting Center XVII - Sofia", Sofia

1612

University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski, Sofia

3124

Emeritus Research, Melbourne

4000

MHAT Trimontium OOD, Plovdiv

4002

"University Multiprofile Hospital for Active Treatment Pulmed", Plovdiv

4027

University Multiprofile Hospital for Active Treatment ''Plovdiv'' AD, Plovdiv

4558

Rheumatology Research Unit, Maroochydore

8200

VITAL MEDICAL CENTER Orvosi es Fogorvosi Kozpont, Veszprém

10117

Innomedica OU, Tallinn

10128

Center for Clinical and Basic Research, Tallinn

11000

Institute of Rheumatology, Belgrade

11312

East Tallinn Central Hospital, Tallinn

15006

Hospital Universitario A Coruna, A Coruña

15706

Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela

18205

Institute for Treatment and Rehabilitation Niska Banja, Niška Banja

41010

Hospital Quironsalud Infanta Luisa, Seville

68601

MEDICAL PLUS s.r.o., Uherské Hradiště

141060

"LLC Family Outpatient clinic #4", Korolyov

150003

State Autonomous Healthcare Institution of Yaroslavl Region, Yaroslavl

185910

"SBHI of the Republic of Karelia Republican Hospital n. a. V.A. Baranov", Petrozavodsk

195257

"Limited Liability Company Sanavita", Saint Petersburg

390026

"FSBEI of HE Ryazan State Medical University n. a academician I.P.Pavlov", Ryazan

390039

"SBI of Ryazan Region Regional Clinical Hospital", Ryazan

410053

"GUZ Regional Clinical Hospital", Saratov

460000

"FGBOU VO Orenburg State Medical University of the Ministry of Health of the Russian Federation", Orenburg

460018

"GBUZ Orenburg Regional Clinical Hospital", Orenburg

600005

"LLC BioMed", Vladimir

748 01

L.K.N. Arthrocentrum s.r.o., Hlučín

530 02

CCR Czech a.s., Pardubice

128 50

Revmatologicky ustav, Prague

130 00

CCR Prague s.r.o., Prague

LT-50161

Hospital of Lithuanian University of Health Sciences, Kauno klinikos, Kaunas

LT-09310

National Osteoporosis Center, Vilnius

15-351

ZDROWIE Osteo-Medic s.c. L. I A. Racewicz, A. i J. Supronik, Bialystok

15-879

ClinicMed Daniluk Nowak Sp. Jawna, Bialystok

20-582

"Zespol Poradni Specjalistycznych REUMED Filia nr 2", Lublin

05-830

NZOZ Lecznica Mak-Med s.c., Nadarzyn

67-100

Twoja Przychodnia - Centrum Medyczne Nowa Sol, Nowa Sól

61-113

Ai Centrum Medyczne Sp. z o.o. Sp. k., Poznan

61-397

Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj, Poznan

96-500

RCMed Oddzial Sochaczew, Sochaczew

87-100

NASZ LEKARZ Przychodnie Medyczne, Torun

02-691

REUMATIKA - Centrum Reumatologii NZOZ, Warsaw

921 12

Narodny ustav reumatickych chorob, Piešťany

058 01

MUDr. Zuzana Cizmarikova, s.r.o., Poprad

979 01

REUMEX s.r.o., Rimavská Sobota

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY